Form 4: Rigel Pharmaceuticals Director Alison L. Hannah Acquires Shares and Options

Alison L. Hannah, a director at Rigel Pharmaceuticals, acquired 25,000 shares of common stock and options for 30,000 shares on May 25, 2024.

Summary

• On May 25, 2024, Alison L. Hannah, a director at Rigel Pharmaceuticals, acquired 25,000 shares of common stock through the vesting of a Restricted Stock Unit (RSU) award.
• These RSUs will fully vest the day before the company's next Annual Meeting, contingent on continuous service on the Board of Directors.
• Hannah also acquired options to purchase 30,000 shares of common stock at an exercise price of $0.9075.
• These options vest monthly over one year from the grant date, also subject to continuous service on the Board of Directors.
• Following these transactions, Hannah directly owns 81,250 shares of Rigel Pharmaceuticals common stock and options for 30,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and options by a director can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.

Future Outlook

The vesting of the Restricted Stock Units is contingent on the Reporting Person's continuous service on the Company's Board of Directors until the date prior to the Company's next Annual Meeting. The stock options vest monthly over one year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates